Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 4/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985022 | 0.87 | CHRNB2 (0.51) | SIGMAR1CHRNB2CHRNA3HTR6CHRNA4 | |
| SCHEMBL1986344 | 0.81 | CHRNB2 (0.51) | SIGMAR1CHRNB2CHRNA3HTR6CHRNA4 | |
| SCHEMBL1986919 | 0.77 | CHRNB2 (0.47) | SIGMAR1CHRNB2CHRNA3HTR6CHRNA4 | |
| SCHEMBL1445173 | 0.70 | SIGMAR1 (1.00) | SIGMAR1HTR6MCHR1 | |
| SCHEMBL1990392 | 0.67 | SIGMAR1 (0.46) | SIGMAR1HTR6MCHR1CHRNA7 | |
| SCHEMBL1985517 | 0.67 | SIGMAR1 (0.46) | SIGMAR1HTR6MCHR1CHRNA7 | |
| SCHEMBL1985618 | 0.67 | SIGMAR1 (0.46) | SIGMAR1HTR6MCHR1CHRNA7 | |
| SCHEMBL2811353 | 0.67 | SIGMAR1 (0.48) | SIGMAR1HTR6 | |
| SCHEMBL1991893 | 0.64 | CDK4 (0.36) | IMPDH2PIK3CD | |
| SCHEMBL28852044 | 0.64 | IMPDH2 (0.53) | IMPDH2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | claimed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| US-8778959-B2 | AZA-bridged ring-fused indoles and indolines | ABBVIE INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152306-A1 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES | INMT, IDO1, IDO2 | SIGMAR1 2033/4885CHRNB2 549/4885CHRNA3 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.